Premium
On the Alert for Cytokine Storm: Immunopathology in COVID ‐19
Author(s) -
Henderson Lauren A.,
Canna Scott W.,
Schulert Grant S.,
Volpi Stefano,
Lee Pui Y.,
Kernan Kate F.,
Caricchio Roberto,
Mahmud Shawn,
Hazen Melissa M.,
Halyabar Olha,
Hoyt Kacie J.,
Han Joseph,
Grom Alexei A.,
Gattorno Marco,
Ravelli Angelo,
Benedetti Fabrizio,
Behrens Edward M.,
Cron Randy Q.,
Nigrovic Peter A.
Publication year - 2020
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.41285
Subject(s) - cytokine storm , covid-19 , immunopathology , cytokine , immunology , betacoronavirus , virology , medicine , infectious disease (medical specialty) , pathology , disease , outbreak
Poor outcomes in COVID‐19 correlate with clinical and laboratory features of cytokine storm syndrome. Broad screening for cytokine storm and early, targeted antiinflammatory therapy may prevent immunopathology and could help conserve limited health care resources. While studies are ongoing, extrapolating from clinical experience in cytokine storm syndromes may benefit the multidisciplinary teams caring for patients with severe COVID‐19.